


East<sup>ab</sup>Bio

High-quality Recombinant  
Protein Manufacturer



# IVD DIAGNOSTIC PROTEINS

# COMPANY PROFILE

High-quality Recombinant Protein Manufacturer

Established In  
**2016**

Company Space  
**10000m<sup>2</sup>**

GMP-standard Workshop  
**4000m<sup>2</sup>**

Large Scale Fermentation  
**Max 1000L**

Biopharm Background Team  
**150<sup>+</sup>**

Industrial grade shaker  
**60<sup>+</sup>**



# QUALITY CERTIFICATION



GMP



ISO13485



ISO9001



ISO45001



ISO14001



# PRODUCT INTRODUCTION

## Cell Culture Proteins (GMP Grade)



### Product

Cytokines, Growth factors, Transferrin, etc.



### Advantages

Animal-free, Low endotoxin, Lot-to-lot consistency, Large-scale production

Deep cooperation with dozens of leading cell culture medium, CGT therapy, organoid and cell-cultivated meat enterprises.

## IVD Diagnostic Proteins



### Product

Antigens and Antibodies such as Respiratory Series, Infectious Disease Series, Digestive Tract Disease Series, etc.



### Advantages

High sensitivity, No cross-reactivity or interference, Large-scale production

Served more than 2 billion disease detections in Europe and North America.

# TECHNOLOGY PLATFORM

## Structural Modification Platforms

- Virtual screening and AI design
- Enzyme directed evolution and rational design
- Antibody structure modelling and optimization

## Application Platforms

- IVD raw materials
- CGT
- Organoid / Organ chips
- Medical enzymes

## Production of Raw Materials

- High density expression fermentation
- High efficiency separation and purification
- Protein formulation screening
- Freeze-drying process

## Recombinant Expression Platforms

- CHO
- HEK293
- E. coli
- Yeast



# CONTENTS

## Respiratory Diseases **01**

---

Influenza A (Flu A)  
Influenza B (Flu B)  
Respiratory Syncytial Virus (RSV)  
Adenovirus (ADV)  
Parainfluenza Virus (HPIV)  
Metapneumovirus (HMPV)  
S. pneumoniae  
Group A streptococcus (Strep A)  
Rhinovirus (RhV)  
Mycoplasma Pneumoniae (MP)

## Digestive Tract Diseases **03**

---

Helicobacter Pylori (HP)  
Adenovirus (ADV)  
Rotavirus (RV)  
Norovirus (NoV)  
Fecal Occult Blood (FOB)  
Transferrin

## Infectious Diseases **04**

---

Monkeypox Virus (MPXV)  
Dengue Virus (DENV)  
Candida Albicans  
Chikungunya virus (CHIKV)

## Diabetes **06**

---

Glycated Hemoglobin A1 (HbA1c)

## Inflammation **06**

---

Serum Amyloid A (SAA)  
Interleukin 6 (IL-6)  
Heparin-Binding Protein (HBP)

## Cardiovascular Markers **07**

---

Soluble Growth Stimulation Expressed Gene2 (ST2)  
Central Nervous System Specific Protein  $\beta$  (S100- $\beta$ )

## Tumor Markers

08

Vascular Endothelial Growth Factor (VEGF)  
Isocitrate Dehydrogenase 1 (IDH1)  
Serum Alpha-FetoProtein (AFP)  
Cytokeratin Fragment 21 (CYFRA21-1)  
Carbohydrate Antigen CA125 (CA125)  
Carcinoembryonic Antigen (CEA)

## Hormones

09

Prolactin (PRL)  
Human Chorionic Gonadotrophin (HCG)

## Drug of Abuse

09

Drug of Abuse

## Veterinary

10

African Swine Fever Virus (ASFV)  
Cat Virus

## General Tool Materials

10

Blocker, RBC, Secondary Ab  
General Tool Materials...

## OEM

11

Respiratory Diseases Uncut Sheet  
Digestive Tract Diseases Uncut Sheet  
Infectious Disease Uncut Sheet  
Latex Enhanced Immune Turbidimetric Reagents  
Nucleic Acid Lateral Flow Strip

## Validation of Featured Products

14

Validation of ADV antibody  
Validation of RSV antibody  
Validation of HPIV antibody  
Validation of HMPV antibody  
Validation of Flu A antibody  
Validation of Flu B antibody



# Respiratory Diseases

Project	Name	Cat#	Type	Application	Recommended Usage
Influenza A (Flu A)	Flu A-NP	A99901	Ag	LFT CLIA	Control
	FluA-mAb	C01907	mAb	LFT CLIA	Capture: C01908
	FluA-mAb	C01908	mAb	LFT CLIA	Detection: C01907
Influenza B (Flu B)	Flu B-NP	A99801	Ag	LFT CLIA	Control
	FluB-mAb	C01911	mAb	LFT CLIA	Capture: C01912
	FluB-mAb	C01912	mAb	LFT CLIA	Detection: C01911
Respiratory Syncytial Virus (RSV)	RSV F0	A00901	Ag	LFT CLIA	Control/Detection
	RSV-mAb	C02702	mAb	LFT CLIA	1: Capture: C02704
	RSV-mAb	C02703	mAb	LFT CLIA	Detection: C02703
	RSV-mAb	C02704	mAb	LFT CLIA	2: Capture: C02704 Detection: C02702
Adenovirus (ADV)	Adv HEXON(His Tag)	A02801	Ag	LFT CLIA	Control/Detection
	Adenovirus mAb	C05303	mAb	LFT CLIA	Capture: C05308
	Adenovirus mAb	C05308	mAb	LFT CLIA	Detection: C05303
Parainfluenza Virus (HPIV)	HPIV1 NP(His Tag)	A06104	Ag	LFT CLIA	Control/Detection
	HPIV1&3 mAb	C06201	mAb	LFT CLIA	Capture: C06202
	HPIV1 mAb	C06202	mAb	LFT CLIA	Detection: C06201
	HPIV2 NP(His Tag)	A06105	Ag	LFT CLIA	Control/Detection
	HPIV2 mAb	C06204	mAb	LFT CLIA	Capture: C06204
	HPIV2 mAb	C06205	mAb	LFT CLIA	Detection: C06205
	HPIV3 NP(His Tag)	A06103-01	Ag	LFT CLIA	Control/Detection

# Respiratory Diseases



Project	Name	Cat#	Type	Application	Recommended Usage
<b>Parainfluenza Virus (HPIV)</b>	HPIV3 mAb	C06203	mAb	LFT CLIA	Capture: C06203
	HPIV1&3 mAb	C06201	mAb	LFT CLIA	Detection: C06201
<b>Metapneumo-virus (HMPV)</b>	HMPV Matrix Protein	A011102	Ag	LFT CLIA	Control/Detection
	HMPV-mAb	C011131	mAb	LFT CLIA	Capture: C011131
	HMPV-mAb	C011132	mAb	LFT CLIA	Detection: C011132
<b>S. pneumoniae</b>	SP-mAb	C09201	mAb	LFT CLIA	Capture: C09201
	SP-mAb	C09202	mAb	LFT CLIA	Detection: C09202
<b>Group A streptococcus (Strep A)</b>	Strep A mAb	C09401	mAb	LFT CLIA	Capture: C09401
	Strep A mAb	C09402	mAb	LFT CLIA	Detection: C09402
<b>Rhinovirus (RhV)</b>	Recombinant Rhinovirus Antigen	A011402	Ag	LFT CLIA	Control
	RhV-mAb	C011401	mAb	LFT CLIA	Capture: C011401
	RhV-mAb	C011402	mAb	LFT CLIA	Detection: C011402
<b>Mycoplasma Pneumoniae (MP)</b>	MP-mAb	C010714	mAb	LFT CLIA	Capture: C010715
	MP-mAb	C010715	mAb	LFT CLIA	Detection: C010714



# Digestive Tract Diseases

Project	Name	Cat#	Type	Application	Recommended Usage
Helicobacter Pylori (HP)	Cag A	A99704	Ag	LFT CLIA	Capture/Detection
	Recombinant H.pylori KatA Antigen	A99706	Ag	LFT CLIA	Control
	HP-mAb	C03010	mAb	LFT CLIA	Capture: C03010
	HP-mAb	C03011	mAb	LFT CLIA	Detection: C03011
Adenovirus (ADV)	Adenovirus mAb	C05303	mAb	LFT CLIA	Capture: C05308
	Adenovirus mAb	C05308	mAb	LFT CLIA	Detection: C05303
Rotavirus (RV)	RV VP6	A99401	Ag	LFT CLIA	Control
	Rotavirus-mAb	C02601	mAb	LFT CLIA	Capture: C02601
	Rotavirus-mAb	C02602	mAb	LFT CLIA	Detection: C02602
Norovirus (NoV)	NoV GI VP1(His Tag)	A09001	Ag	LFT CLIA	Control
	Norovirus GI mAb	C020501	mAb	LFT CLIA	Capture: C020501
	Norovirus GI mAb	C020504	mAb	LFT CLIA	Detection: C020504
	NoV GII-4 VP1(His Tag)	A09002	Ag	LFT CLIA	Control
	Norovirus GII mAb	C020521	mAb	LFT CLIA	Capture: C020521
	Norovirus GII mAb	C020522	mAb	LFT CLIA	Detection: C020522
Fecal Occult Blood (FOB)	FOB-mAb	C02801	mAb	LFT CLIA	Capture: C02801
	FOB-mAb	C02802	mAb	LFT CLIA	Detection: C02802
Transferrin	Recombinant Human Transferrin	A021201	Ag	LFT CLIA	Control
	Transferrin-mAb	C05501	mAb	LFT CLIA	Capture: C05308
	Transferrin-mAb	C05502	mAb	LFT CLIA	Detection: C05303

# Infectious Diseases



Project	Name	Cat#	Type	Application	Recommended Usage	
Monkeypox Virus (MPXV)	MPXV A29L Protein(His Tag)	A05107-10	Ag	LFT CLIA	Control	
	MPXV A29L mAb	C05137	mAb	LFT CLIA	1: Capture C05137 Detection C05138 2: Capture C05137 Detection C05139	
	MPXV A29L mAb	C05138	mAb	LFT CLIA		
	MPXV A29L mAb	C05139	mAb	LFT CLIA		
	MPXV M1R Protein(His Tag)	A05105-10	Ag	LFT CLIA	Control	
	MPXV MIR mAb	C05115	mAb	LFT CLIA	1: Capture C05115 Detection C05116 2: Capture C05115 Detection C05117	
	MPXV MIR mAb	C05116	mAb	LFT CLIA		
	MPXV MIR mAb	C05117	mAb	LFT CLIA		
	MPXV A35R Protein(His Tag)	A05111-10	Ag	LFT CLIA	Control	
	MPXV A35R mAb	C05174	mAb	LFT CLIA	Capture: C05175 Detection: C05174	
	MPXV A35R mAb	C05175	mAb	LFT CLIA		
	Dengue Virus (DENV)	DENV1-NS1	A00201	Ag	LFT CLIA	Control
		DENV2-NS1	A00202	Ag	LFT CLIA	Control
		DENV3-NS1	A00203	Ag	LFT CLIA	Control
DENV4-NS1		A00204	Ag	LFT CLIA	Control	
DENV mAb		C030733	mAb	LFT CLIA	Capture: C030733 Detection: C030734	
DENV mAb		C030734	mAb	LFT CLIA		
DENV2-E		A00206	Ag	LFT CLIA	Capture/Detection, for IgG test	
DENV3-E		A00207	Ag	LFT CLIA		
DENV4-E		A00208	Ag	LFT CLIA		



# Infectious Diseases

Project	Name	Cat#	Type	Application	Recommended Usage
Dengue Virus (DENV)	DENV-E	A00209	Ag	LFT CLIA	Capture/Detection, for IgM test
	DENV1-EnV	A030711	Ag	LFT CLIA	
	DENV2-EnV	A030712	Ag	LFT CLIA	
	DENV3-EnV	A030713	Ag	LFT CLIA	
	DENV4-EnV	A030714	Ag	LFT CLIA	
Candida Albicans	Candida albicans mAb	C09301	mAb	LFT	Capture: C09301
	Candida albicans mAb	C09302	mAb	LFT	Detection: C09302
Chikungunya virus (CHIKV)	Recombinant CHIKV E1 fragment ED1+2	A032303	Ag	LFT CLIA	Control/Capture/Detection
	Recombinant CHIKV E1 fragment ED3	A032302	Ag	LFT CLIA	Control/Capture/Detection
	Recombinant CHIKV E2	A032301	Ag	LFT CLIA	Control/Capture/Detection

# Diabetes



Project	Name	Cat#	Type	Application	Recommended Usage
Glycated Hemoglobin A1c (HbA1c)	HbA1c mAb	C03803	mAb	CLIA	Detection
	HbA1c mAb	C080121	mAb	TIA	Detection

# Inflammation



Project	Name	Cat#	Type	Application	Recommended Usage
Serum Amyloid A (SAA)	SAA-mAb	C03101	mAb	LFT CLIA TIA	Capture: C03102 Detection: C03101
	SAA-mAb	C03102	mAb	LFT CLIA TIA	
Interleukin 6 (IL-6)	Recombinant Human IL-6	A040101	Ag	LFT CLIA	Control
	IL6-mAb	C00504	mAb	LFT CLIA	Capture: C00505 Detection: C00504
	IL6-mAb	C00505	mAb	LFT CLIA	
Heparin-Binding Protein (HBP)	HBP(His Tag)	A01301	Ag	LFT CLIA TIA	Control
	HBP-mAb	C06001	mAb	LFT CLIA	Capture: C06002 Detection: C06001
	HBP-mAb	C06002	mAb	LFT CLIA	



# Cardiovascular Markers

Project	Name	Cat#	Type	Application	Recommended Usage
Soluble Growth Stimulation Expressed Gene2(ST2)	ST2(His Tag)	A05801	Ag	LFT CLIA	Control
	ST2-mAb	C05801	mAb	LFT CLIA	Capture: C05802
	ST2-mAb	C05802	mAb	LFT CLIA	Detection: C05801
Central Nervous System Specific Protein $\beta$ (S100- $\beta$ )	S100 $\beta$	A05901	Ag	LFT CLIA	Control
	S100 $\beta$ -mAb	C05901	mAb	LFT CLIA	Capture: C05902
	S100 $\beta$ -mAb	C05902	mAb	LFT CLIA	Detection: C05901

# Tumor Markers



Project	Name	Cat#	Type	Application	Recommended Usage
	VEGF(His Tag)	A060801	Ag	LFT CLIA	Control
Vascular Endothelial Growth Factor(VEGF)	VEGF-mAb	C00907	mAb	LFT CLIA	1: Capture: C00908 Detection: C00907
	VEGF-mAb	C00908	mAb	LFT CLIA	2: Capture: C00909 Detection: C00908
	VEGF-mAb	C00909	mAb	LFT CLIA	
Isocitrate Dehydrogenase 1 (IDH1)	IDH1-mAb	C08301	mAb	LFT CLIA	Capture: C08302 Detection: C08301
	IDH1-mAb	C08302	mAb	LFT CLIA	
Serum Alpha-FetoProtein (AFP)	AFP-mAb	C08401	mAb	LFT CLIA	Capture: C08401 Detection: C08402
	AFP-mAb	C08402	mAb	LFT CLIA	
Cytokeratin Fragment 21 (CYFRA21-1)	CYFRA21-1 mAb	C08601	mAb	LFT CLIA	Capture: C08602 Detection: C08601
	CYFRA21-1 mAb	C08602	mAb	LFT CLIA	
Carbohydrate Antigen CA125 (CA125)	CA125-mAb	C08701	mAb	LFT CLIA	Capture: C08702 Detection: C08701
	CA125-mAb	C08702	mAb	LFT CLIA	
Carcinoembryonic Antigen(CEA)	CEA-mAb	C08901	mAb	LFT CLIA	Capture: C08902 Detection: C08901
	CEA-mAb	C08902	mAb	LFT CLIA	



# Hormones

Project	Name	Cat#	Type	Application	Recommended Usage
Prolactin (PRL)	Human Prolactin(His Tag)	A070101	Ag	LFT CLIA	Control
	Prolactin-mAb	C05201	mAb	LFT CLIA	Capture: C05201
	Prolactin-mAb	C05202	mAb	LFT CLIA	Detection: C05202
Human Chorionic Gonadotrophin (HCG)	HCG-mAb	C070201	mAb	LFT CLIA	Capture: C070201
	HCG-mAb	C070203	mAb	LFT CLIA	Detection: C070203



# Drug of Abuse

Project	Name	Cat#	Type	Application	Recommended Usage
Drug of Abuse	K2-mAb	C03701	mAb	LFT	Detection
	THC-mAb	C03201	mAb	LFT	Detection
	FEN1-mAb	C03301	mAb	LFT	Detection

# Veterinary



Project	Name	Cat#	Type	Application	Recommended Usage
African Swine Fever Virus (ASFV)	ASFV P72(His Tag)	A01007-1	Ag	LFT CLIA ELISA	Capture/Detection
	FelV P27 (His Tag)	A01901	Ag	LFT	Capture/Detection
Cat Virus	FHV-1 gD(His Tag)	A02401	Ag	LFT	Capture/Detection

## General Tool Materials



Project	Name	Cat#	Type	Application	Recommended Usage
Blocker, RBC, Secondary Ab, General Tool Materials...	Blocker	C04002	mAb	LFT CLIA TIA	Block interference
	Blocker	C04003	mAb	LFT CLIA TIA	Block interference
	RBC-mAb	C04501	mAb	LFT	Adsorption of red blood cells
	Mouse anti-Human IgG	C01206	mAb	LFT CLIA	Second Ab
	Mouse anti-Human IgM	C01204	mAb	LFT CLIA	Second Ab
	IgE-mAb	C02103	mAb	LFT CLIA	Second Ab
	IgE-mAb	C02102	mAb	LFT CLIA	Total IgE Detection Capture: C02103
	IgE-mAb	C02103	mAb	LFT CLIA	Detection: C02102
	IgE-mAb	C02104	mAb	LFT CLIA	Second Ab



# OEM

## Respiratory Diseases Uncut Sheet

Name	Cat#	Sample Type	Specifications
Influenza A antigen rapid test uncut sheet (colloidal gold method)	FA01	Nasopharyngeal Swab	6cm×30cm
Influenza A antigen rapid test uncut sheet (latex method)	FA02	Nasopharyngeal Swab	6cm×30cm
Influenza B antigen rapid test uncut sheet (colloidal gold method)	FB01	Nasopharyngeal Swab	6cm×30cm
Influenza B antigen rapid test uncut sheet (latex method)	FB02	Nasopharyngeal Swab	6cm×30cm
Flu A&B antigen rapid test uncut sheet (colloid gold method)	FAB01	Nasopharyngeal Swab	6cm×30cm
Flu A&B antigen rapid test uncut sheet (latex method)	FAB02	Nasopharyngeal Swab	6cm×30cm
Respiratory Syncytial Virus antigen rapid test uncut sheet(colloidal gold method)	RSV01	Nasopharyngeal Swab	6cm×30cm
Respiratory Syncytial Virus antigen rapid test uncut sheet (latex method)	RSV02	Nasopharyngeal Swab	6cm×30cm
Adenovirus antigen rapid test uncut sheet (colloidal gold method)	ADV01	Nasopharyngeal Swab	6cm×30cm
Adenovirus antigen rapid test uncut sheet (latex method)	ADV02	Nasopharyngeal Swab	6cm×30cm
RSV&ADV antigen rapid test uncut sheet (colloidal gold method)	RSV-ADV01	Nasopharyngeal Swab	6cm×30cm
RSV&ADV antigen rapid test uncut sheet(latex method)	RSV-ADV02	Nasopharyngeal Swab	6cm×30cm
Metapneumovirus antigen rapid test uncut sheet (colloidal gold method)	HMPV01	Nasopharyngeal Swab	6cm×30cm
HPIV antigen rapid test uncut sheet (colloidal gold method)	HPIV401A	Nasopharyngeal Swab	6cm×30cm
Sars Cov2 antigen rapid test uncut sheet (colloidal gold method)	SC01	Nasopharyngeal Swab	6cm×30cm
Sars Cov2 antigen rapid test uncut sheet (latex method)	SC02	Nasopharyngeal Swab	6cm×30cm

## Digestive Tract Diseases Uncut Sheet

Name	Cat#	Sample Type	Specifications
Helicobacter pylori antigen rapid test uncut sheet(colloidal gold method)	HP01	Stool	6cm×30cm
Helicobacter pylori antigen rapid test uncut sheet (latex method)	HP02	Stool	6cm×30cm
Rotavirus antigen rapid test uncut sheet(colloidal gold method)	RV01A	Stool	6cm×30cm
Fecal Occult Blood rapid test uncut sheet(colloidal gold method)	FOB01	Stool	6cm×30cm
Transferrin antigen rapid test uncut sheet (latex method)	TRF01	Stool	6cm×30cm

## Infectious Diseases Uncut Sheet

Name	Cat#	Sample Type	Specifications
DENV1-4 NS1 rapid test uncut sheet(colloidal gold method)	DVNS01	Whole blood Serum Plasma	6cm×30cm
DENV1-4 NS1 antigen rapid test uncut sheet (latex method)	DVNS02	Whole blood Serum Plasma	6cm×30cm
DENV IgG antibody rapid test uncut sheet(colloidal gold method)	DVG01	Whole blood Serum Plasma	6cm×30cm
Monkeypox virus antigen rapid test uncut sheet (colloidal gold method)	A2901A	Skin lesion specimen Oropharyngeal swab   Serum	6cm×30cm
Pv antigen rapid test uncut sheet (colloidal gold method)	PV01	Whole blood	6cm×30cm
Pv antigen rapid test uncut sheet (latex method)	PV02	Whole blood	6cm×30cm
Pf antigen rapid test uncut sheet (colloidal gold method)	PF01	Whole blood	6cm×30cm
Pf antigen rapid test uncut sheet (latex method)	PF02	Whole blood	6cm×30cm
Pv & Pf antigen rapid test uncut sheet (colloidal gold method)	PVPF01	Whole blood	6cm×30cm
Pv & Pf antigen rapid test uncut sheet (latex method)	PVPF02	Whole blood	6cm×30cm
Pan antigen rapid test uncut sheet (colloidal gold method)	PAN01	Whole blood	6cm×30cm
Pan antigen rapid test uncut sheet (latex method)	PAN02	Whole blood	6cm×30cm



# OEM

## Latex Enhanced Immune Turbidimetric Reagents

Name	Cat#	Sample Type	Range	Wavelength	Application
SAA Latex enhanced immune turbidimetry	SAA01	Serum Plasma	2-300 mg/L	546 nm	Various biochemical analyzer
D-Dimer Latex enhanced immune turbidimetry	DD01	Serum Plasma	0.5-30mg/L	570nm	Various biochemical analyzer
HbA1c Latex immune turbidimetry	A1C01	Whole blood	2%-20%	660nm	Various biochemical analyzer
25-OHVD Latex enhanced immune turbidimetry	VD01	Serum Plasma	2-150ng/mL	700nm	Various biochemical analyzer
25-OHVD Latex enhanced immune turbidimetry	VD02	Serum Plasma	2-150ng/mL	700nm	Various biochemical analyzer

## Nucleic Acid Lateral Flow Strip

Name	Cat#	Application	Specifications
Nucleic Acid Lateral Flow Strip	NAS01A	FITC  6-FAM	50 T
Dualplex Nucleic Acid Lateral Flow Strip	NAS02A	FITC  6-FAM  Digoxigenin	50 T

# Validation of ADV Antibody




## Activity

The recombinant antigens of Adenovirus (ADV) types 1, 2, 3, 4, 7, and 55 were detected, with a minimum detection limit of 0.1 ng/mL.

Colloidal gold platform antibody pairing performance:

Control	Concentration	Result
ADV 1	1ng/mL	G3
ADV 1	0.1ng/mL	G1
ADV 2	1ng/mL	G3
ADV 2	0.1ng/mL	G1
ADV 3	1ng/mL	G1
ADV 3	0.1ng/mL	G0

Control	Concentration	Result
ADV 4	1ng/mL	G1
ADV 4	0.1ng/mL	G0
ADV 7	1ng/mL	G1
ADV 7	0.1ng/mL	G0
ADV 55	1ng/mL	G3
ADV 55	0.1ng/mL	G1



## Specificity

115 normal human nasopharyngeal swabs were tested, and no non-specific reactions were observed.

## Cross-Reactivity

Cross-reactivity tests were conducted with various pathogens, including SARS-CoV-2, Influenza A, Influenza B, Parainfluenza virus, Respiratory Syncytial Virus, and Human Metapneumovirus. No cross-reactivity was detected. Detailed results are shown below:

Pathogen	Concentration	Result
SARS-CoV-2	$\sim 1 \times 10^7$ TCID50/mL	G0
Flu A H1N1	$\sim 1 \times 10^7$ TCID50/mL	G0
Flu A H3N2	$\sim 1 \times 10^7$ TCID50/mL	G0
Flu B V	$\sim 1 \times 10^7$ TCID50/mL	G0
Flu B Y	$\sim 1 \times 10^7$ TCID50/mL	G0
HPIV I	10 $\mu$ g/mL	G0

Pathogen	Concentration	Result
HPIV II	10 $\mu$ g/mL	G0
HPIV III	10 $\mu$ g/mL	G0
RSV A	$\sim 1 \times 10^7$ TCID50/mL	G0
RSV B	$\sim 1 \times 10^7$ TCID50/mL	G0
HMPV M	10 $\mu$ g/mL	G0
HMPV N	10 $\mu$ g/mL	G0



# Validation of RSV Antibody

## Activity

Respiratory Syncytial Virus (RSV) antigen was detected at 1 ng/mL, with a minimum detection limit of 0.1 ng/mL.

Colloidal gold platform antibody pairing performance:

Control	Pairing (F Protein)	Pairing (N Protein)	Control	Pairing (F Protein)	Pairing (N Protein)
RSV F 10ng/mL	G5	G0	RSV A 1:100	G7	G7
RSV F 1ng/mL	G3	G0	RSV A 1:1000	G5	G5
RSV F 0.1ng/mL	G1	G0	RSV A 1:10000	G3	G3
RSV N 10ng/mL	G0	G4	RSV B 1:100	G7	G7
RSV N 1ng/mL	G0	G2	RSV B 1:1000	G5	G5
RSV N 0.1ng/mL	G0	G1	RSV B 1:10000	G3	G3

## Specificity

104 normal human nasopharyngeal swabs were tested, and no non-specific reactions were observed.

## Cross-Reactivity

Cross-reactivity tests were conducted with various pathogens, including SARS-CoV-2, Influenza A, Influenza B, Parainfluenza virus, Adenovirus, and Human Metapneumovirus. No cross-reactivity was detected. Detailed results are shown below:

Pathogen	Concentration	Result	Pathogen	Concentration	Result
SARS-CoV-2	$\sim 1 \times 10^7$ TCID50/mL	G0	HPIV II	10 $\mu$ g/mL	G0
Flu A H1N1	$\sim 1 \times 10^7$ TCID50/mL	G0	HPIV III	10 $\mu$ g/mL	G0
Flu A H3N2	$\sim 1 \times 10^7$ TCID50/mL	G0	ADV 3	$\sim 1 \times 10^7$ TCID50/mL	G0
Flu B V	$\sim 1 \times 10^7$ TCID50/mL	G0	ADV 7	$\sim 1 \times 10^7$ TCID50/mL	G0
Flu B Y	$\sim 1 \times 10^7$ TCID50/mL	G0	HMPV M	10 $\mu$ g/mL	G0
HPIV I	10 $\mu$ g/mL	G0	HMPV N	10 $\mu$ g/mL	G0

# Validation of HPIV Antibody




## Activity

Human Parainfluenza virus (HPIV) antigen was detected at 10 ng/mL, with a minimum detection limit of 1 ng/mL.

Colloidal gold platform antibody pairing performance:

Control	Pairing (Type I)	Pairing (Type II)	Pairing (Type III)	Control	Pairing (Type I)	Pairing (Type II)	Pairing (Type III)
HPIV I N 10ng/mL	G2	G0	G0	HPIV I 1:100	G3	G0	G0
HPIV I N 1ng/mL	G0	G0	G0	HPIV I 1:1000	G1	G0	G0
HPIV II N 10ng/mL	G0	G3	G0	HPIV II 1:100	G0	G2	G0
HPIV II N 1ng/mL	G0	G1	G0	HPIV II 1:1000	G0	G1	G0
HPIV III N 10ng/mL	G0	G0	G4	HPIV III 1:100	G0	G0	G3
HPIV III N 1ng/mL	G0	G0	G2	HPIV III 1:1000	G0	G0	G1



## Specificity

127 normal human nasopharyngeal swabs were tested, and no non-specific reactions were observed.

## Cross-Reactivity

Cross-reactivity tests were conducted with various pathogens, including SARS-CoV-2, Influenza A, Influenza B, Respiratory Syncytial Virus, Adenovirus, and Human Metapneumovirus. No cross-reactivity was detected. Detailed results are shown below:

Pathogen	Concentration	Result
SARS-CoV-2	$\sim 1 \times 10^7$ TCID50/mL	G0
Flu A H1N1	$\sim 1 \times 10^7$ TCID50/mL	G0
Flu A H3N2	$\sim 1 \times 10^7$ TCID50/mL	G0
Flu B V	$\sim 1 \times 10^7$ TCID50/mL	G0
Flu B Y	$\sim 1 \times 10^7$ TCID50/mL	G0
RSVA	$\sim 1 \times 10^7$ TCID50/mL	G0

Pathogen	Concentration	Result
RSVB	$\sim 1 \times 10^7$ TCID50/mL	G0
ADV 3	$\sim 1 \times 10^7$ TCID50/mL	G0
ADV 7	$\sim 1 \times 10^7$ TCID50/mL	G0
HMPV M	10 $\mu$ g/mL	G0
HMPV N	10 $\mu$ g/mL	G0



# Validation of HMPV Antibody


## Activity

Human Metapneumovirus (HMPV) M protein was detected at 0.5 ng/mL, with a minimum detection limit of 0.1 ng/mL.

Colloidal gold platform antibody pairing performance:

Control	Concentration	Result
HMPV M	1ng/mL	G5
HMPV M	0.5ng/mL	G3
HMPV M	0.1ng/mL	G1
HMPV A1	1:1000	G5
HMPV A1	1:10000	G2
HMPV A2	1:1000	G6

Control	Concentration	Result
HMPV A2	1:10000	G3
HMPV B1	1:1000	G4
HMPV B1	1:10000	G2
HMPV B2	1:1000	G5
HMPV B2	1:10000	G2



## Specificity

103 normal human nasopharyngeal swabs were tested, and no non-specific reactions were observed.

## Cross-Reactivity

Cross-reactivity tests were conducted with various pathogens, including SARS-CoV-2, Influenza A, Influenza B, Parainfluenza virus, Respiratory Syncytial Virus, and Adenovirus. No cross-reactivity was detected. Detailed results are shown below:

Pathogen	Concentration	Result
SARS-CoV-2	$\sim 1 \times 10^7$ TCID50/mL	G0
Flu A H1N1	$\sim 1 \times 10^7$ TCID50/mL	G0
Flu A H3N2	$\sim 1 \times 10^7$ TCID50/mL	G0
Flu B V	$\sim 1 \times 10^7$ TCID50/mL	G0
Flu B Y	$\sim 1 \times 10^7$ TCID50/mL	G0
HPIV I	10 $\mu$ g/mL	G0

Pathogen	Concentration	Result
HPIV II	10 $\mu$ g/mL	G0
HPIV III	10 $\mu$ g/mL	G0
RSV A	$\sim 1 \times 10^7$ TCID50/mL	G0
RSV B	$\sim 1 \times 10^7$ TCID50/mL	G0
ADV 3	$\sim 1 \times 10^7$ TCID50/mL	G0
ADV 7	$\sim 1 \times 10^7$ TCID50/mL	G0

# Validation of Flu A Antibody




## Activity

Influenza A virus (Flu A) antigen was detected at 1 ng/mL, with a minimum detection limit of 0.1 ng/mL.

Colloidal gold platform antibody pairing performance:

Control	Pairing 1	Pairing 2
Flu A Ag 10ng/mL	G5	G6
Flu A Ag 1ng/mL	G3	G4
Flu A Ag 0.5ng/mL	G1	G2
Flu A Ag 0.1ng/mL	G0	G1
Flu A H1N1 1:100	G5	G5
Flu A H1N1 1:1000	G3	G4
Flu A H1N1 1:10000	G1	G2

Control	Pairing 1	Pairing 2
Flu A H1N1pdm 1:100	G5	G6
Flu A H1N1pdm 1:1000	G3	G3
Flu A H1N1pdm 1:10000	G1	G2
Flu A H3N2 1:100	G7	G8
Flu A H3N2 1:1000	G5	G6
Flu A H3N2 1:10000	G3	G4



## Specificity

127 normal human nasopharyngeal swabs were tested, and no non-specific reactions were observed.

## Cross-Reactivity

Cross-reactivity tests were conducted with various pathogens, including SARS-CoV-2, Influenza B, Parainfluenza virus, Respiratory Syncytial Virus, Adenovirus, and Human Metapneumovirus. No cross-reactivity was detected. Detailed results are shown below:

Pathogen	Concentration	Result
SARS-CoV-2	$\sim 1 \times 10^7$ TCID50/mL	G0
Flu B V	$\sim 1 \times 10^7$ TCID50/mL	G0
Flu B Y	$\sim 1 \times 10^7$ TCID50/mL	G0
HPIV I	10 $\mu$ g/mL	G0
HPIV II	10 $\mu$ g/mL	G0
HPIV III	10 $\mu$ g/mL	G0

Pathogen	Concentration	Result
RSVA	$\sim 1 \times 10^7$ TCID50/mL	G0
RSVB	$\sim 1 \times 10^7$ TCID50/mL	G0
ADV 3	$\sim 1 \times 10^7$ TCID50/mL	G0
ADV 7	$\sim 1 \times 10^7$ TCID50/mL	G0
HMPV M	10 $\mu$ g/mL	G0
HMPV N	10 $\mu$ g/mL	G0



# Validation of Flu B Antibody


## Activity

Influenza B virus (Flu B) antigen was detected at 1 ng/mL, with a minimum detection limit of 0.1 ng/mL.

Colloidal gold platform antibody pairing performance:

Control	Concentration	Result
Flu B Ag	10ng/mL	G6
Flu B Ag	1ng/mL	G4
Flu B Ag	0.5ng/mL	G3
Flu B Ag	0.1ng/mL	G1
B/Brisbane/1/07	1:100	G5

Control	Concentration	Result
B/Brisbane/1/07	1:1000	G3
B/Brisbane/1/07	1:10000	G1
B/Guangdong/120/00	1:100	G7
B/Guangdong/120/00	1:1000	G5
B/Guangdong/120/00	1:10000	G3



## Specificity

119 normal human nasopharyngeal swabs were tested, and no non-specific reactions were observed.

## Cross-Reactivity

Cross-reactivity tests were conducted with various pathogens, including SARS-CoV-2, Influenza A, Parainfluenza virus, Respiratory Syncytial Virus, Adenovirus, and Human Metapneumovirus. No cross-reactivity was detected. Detailed results are shown below:

Pathogen	Concentration	Result
SARS-CoV-2	$\sim 1 \times 10^7$ TCID <sub>50</sub> /mL	G0
Flu A H1N1	$\sim 1 \times 10^7$ TCID <sub>50</sub> /mL	G0
Flu A H3N2	$\sim 1 \times 10^7$ TCID <sub>50</sub> /mL	G0
HPIV I	10 $\mu$ g/mL	G0
HPIV II	10 $\mu$ g/mL	G0
HPIV III	10 $\mu$ g/mL	G0

Pathogen	Concentration	Result
RSV A	$\sim 1 \times 10^7$ TCID <sub>50</sub> /mL	G0
RSV B	$\sim 1 \times 10^7$ TCID <sub>50</sub> /mL	G0
ADV 3	$\sim 1 \times 10^7$ TCID <sub>50</sub> /mL	G0
ADV 7	$\sim 1 \times 10^7$ TCID <sub>50</sub> /mL	G0
HMPV M	10 $\mu$ g/mL	G0
HMPV N	10 $\mu$ g/mL	G0



## Jiangsu East-Mab Biomedical Technology Co., Ltd.

 +86 400 998 0106  [www.eastmabbio.com](http://www.eastmabbio.com)  [contact@eastmab.com](mailto:contact@eastmab.com)

 **R&D and Production Center** : Building 13 & 17, 888 Zhujiang Rd, Nantong, Jiangsu 226499 , China

**Application Center** : Floor 5 & 6, Building 1, 168 Majian Rd, Suzhou, Jiangsu 215129, China